Dolutegravir Pharmacokinetics During Weekly Rifapentine/Isoniazid for TB Prevention

PHASE1RecruitingINTERVENTIONAL
Enrollment

25

Participants

Timeline

Start Date

November 15, 2024

Primary Completion Date

February 28, 2027

Study Completion Date

June 30, 2027

Conditions
Pediatric HIV InfectionLatent Tuberculosis
Interventions
DRUG

Rifapentine

Children 2-11 years received standard HIV treatment and 3HP (RPT/INH weekly for 12 weeks) for TB prevention. Children \<2 years receive standard HIV treatment, a single-dose of extrapolated weekly RPT/INH, followed by standard INH prophylaxis. Safety and pharmacokinetics will be evaluated.

DRUG

Dolutegravir

All children in this study are living with HIV and thus dolutegravir is a standard part of treatment; in this study we will collect blood samples to measure dolutegravir levels during combination treatment with rifapentine/isoniazid treatment for TB prevention

Trial Locations (1)

Nigeria

RECRUITING

University College Hospital, Ibadan

All Listed Sponsors
collaborator

APIN Public Health Initiatives

UNKNOWN

collaborator

University of Cape Town

OTHER

lead

Brigham and Women's Hospital

OTHER